Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 21, doi. 10.3390/antib11010021
- By:
- Publication type:
- Article
Works matching IS 20734468 AND DT 2022 AND VI 11 AND IP 1
Results: 21
1
2
Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 20, doi. 10.3390/antib11010020
- By:
- Publication type:
- Article
3
More Than Meets the Kappa for Antibody Superantigen Protein L (PpL).
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 14, doi. 10.3390/antib11010014
- By:
- Publication type:
- Article
4
Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 18, doi. 10.3390/antib11010018
- By:
- Publication type:
- Article
5
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 17, doi. 10.3390/antib11010017
- By:
- Publication type:
- Article
6
The Role of Bispecific Antibodies in Non-Hodgkin's Lymphoma: From Structure to Prospective Clinical Use.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 16, doi. 10.3390/antib11010016
- By:
- Publication type:
- Article
7
Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 15, doi. 10.3390/antib11010015
- By:
- Publication type:
- Article
8
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 19, doi. 10.3390/antib11010019
- By:
- Publication type:
- Article
9
Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 13, doi. 10.3390/antib11010013
- By:
- Publication type:
- Article
10
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 12, doi. 10.3390/antib11010012
- By:
- Publication type:
- Article
11
Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 11, doi. 10.3390/antib11010011
- By:
- Publication type:
- Article
12
Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 10, doi. 10.3390/antib11010010
- By:
- Publication type:
- Article
13
Acknowledgment to Reviewers of Antibodies in 2021.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 9, doi. 10.3390/antib11010009
- Publication type:
- Article
14
Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 8, doi. 10.3390/antib11010008
- By:
- Publication type:
- Article
15
Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 7, doi. 10.3390/antib11010007
- By:
- Publication type:
- Article
16
Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 6, doi. 10.3390/antib11010006
- By:
- Publication type:
- Article
17
New Opportunities in Glycan Engineering for Therapeutic Proteins.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 5, doi. 10.3390/antib11010005
- By:
- Publication type:
- Article
18
TCDD Inhibition of IgG1 Production in Experimental Autoimmune Encephalomyelitis (EAE) and In Vitro.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 4, doi. 10.3390/antib11010004
- By:
- Publication type:
- Article
19
Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 3, doi. 10.3390/antib11010003
- By:
- Publication type:
- Article
20
Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules.
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 2, doi. 10.3390/antib11010002
- By:
- Publication type:
- Article
21
Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?
- Published in:
- Antibodies (2073-4468), 2022, v. 11, n. 1, p. 1, doi. 10.3390/antib11010001
- By:
- Publication type:
- Article